Articles

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic…

October 2, 2023

3:24 pm

Articles

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD…

May 11, 2023

8:28 am

Articles

atai Life Sciences to Participate in Upcoming May Investor Conference

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…

May 2, 2023

8:27 am

Articles

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

– Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW…

April 28, 2023

8:26 am

Uncategorized

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…

April 13, 2023

8:23 am

News

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living…

March 24, 2023

8:22 am